Racura Oncology Says Safety Review Committee Approved Planned Dose Escalation in Phase 1 Lung Cancer Combination Therapy Trial
MT Newswires Live
Yesterday
Racura Oncology (ASX:RAC) said the Safety Review Committee has cleared RC220 to move to the next planned dose level of 100 milligrams per square meter in the phase one Harness-1 trial, according to a Monday filing with the Australian bourse.
The trial is assessing the safety and tolerability of the company's RC220, an intravenous formulation of anti-cancer drug bisantrene in combination with osimertinib in patients with epidermal growth factor receptor-mutant non-small cell lung cancer, the filing said.
The committee found no dose-limiting toxicities or treatment-related concerns in group one patients during the safety observation period, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.